{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kumar A"],"funding":["NCI NIH HHS"],"pagination":["508-514"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9620550"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["166(3)"],"pubmed_abstract":["<h4>Objective</h4>We sought to determine the predictive value of combining tumor molecular subtype and computerized tomography (CT) imaging for surgical outcomes after primary cytoreductive surgery in advanced stage high-grade serous ovarian cancer (HGSOC) patients.<h4>Methods</h4>We identified 129 HGSOC patients who underwent pre-operative CT imaging and post-operative tumor mRNA profiling. A continuous CT-score indicative of overall disease burden was defined based on six imaging measurements of anatomic involvement. Molecular subtypes were derived from mRNA profiling of chemo-naïve tumors and classified as mesenchymal (MES) subtype (36%) or non-MES subtype (64%). Fischer exact tests and multivariate logistic regression examined residual disease and surgical complexity.<h4>Results</h4>Wo"],"journal":["Gynecologic oncology"],"pubmed_title":["Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer."],"pmcid":["PMC9620550"],"funding_grant_id":["R01 CA172404","R01 CA248288"],"pubmed_authors":["Sheedy SP","Kim B","Winham SJ","Anglesio MS","Wang C","Ramus SJ","Torres D","McCauley BM","Keeney GL","Cliby WA","Kumar A","Goode EL"],"additional_accession":[]},"is_claimable":false,"name":"Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer.","description":"<h4>Objective</h4>We sought to determine the predictive value of combining tumor molecular subtype and computerized tomography (CT) imaging for surgical outcomes after primary cytoreductive surgery in advanced stage high-grade serous ovarian cancer (HGSOC) patients.<h4>Methods</h4>We identified 129 HGSOC patients who underwent pre-operative CT imaging and post-operative tumor mRNA profiling. A continuous CT-score indicative of overall disease burden was defined based on six imaging measurements of anatomic involvement. Molecular subtypes were derived from mRNA profiling of chemo-naïve tumors and classified as mesenchymal (MES) subtype (36%) or non-MES subtype (64%). Fischer exact tests and multivariate logistic regression examined residual disease and surgical complexity.<h4>Results</h4>Wo","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-04T09:41:48.097Z","creation":"2025-04-04T09:41:48.097Z"},"accession":"S-EPMC9620550","cross_references":{"pubmed":["35931468"],"doi":["10.1016/j.ygyno.2022.07.020"]}}